BioNTech COO Sean Marett Reveals How To Spend $270M
Executive Summary
BioNTech AG raised $270m in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. COO Sean Marett tells Scrip how the funds will be invested.
You may also be interested in...
Sanofi Takes €80M BioNTech Stake & Extends 2015 Deal
BioNTech gets an €80m boost to its reserves as Sanofi takes equity stake as partners extend 2015 deal and advance an mRNA-based cancer immunotherapy into clinic against multiple solid tumors
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.